Intensified inhibition of renin-angiotensin system: A way to improve renal protection?

Current Hypertension Reports

Volumn 9, Issue 5, 2007, Pages 430-436

  Cravedi, Paolo ^a   Ruggenenti, Piero ^b   Remuzzi, Giuseppe ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RAMIPRIL; RENIN INHIBITOR; RESERPINE; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN;

ADD ON THERAPY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; GLOMERULOSCLEROSIS; GYNECOMASTIA; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPOTENCE; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENSTRUATION DISORDER; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PROTEINURIA; REMISSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTILIPEMIC AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDIES AS TOPIC; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RENIN-ANGIOTENSIN SYSTEM;

EID: 36849060128     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0078-3     Document Type: Review

References (51)

1. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001, 12:2753-2758.
2. Jafar TH, Stark PC, Schmid CH, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med 2001, 135:73-87.
3. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799-812.
4. Campbell R, Sangalli F, Perticucci E, et al.: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003, 63:1094-1103.
5. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitors in nondiabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003, 361:117-124.
6. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448.
7. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288.
8. Macconi D, Macconi D, Abbate M, et al.: Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 2006, 168:1073.
9. Rudnicki M, Eder S, Perco P, et al.: Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidey Int 2007, 71:325-335.
10. Zoja C, Morigi M, Remuzzi G: Proteinuria and phenotypic change of proximal tubular cells. J Am Soc Nephrol 2003, 14:S36-S41.
11. Cameron JS, Turner DR, Ogg CS, et al.: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978, 10:213-218.
12. Remuzzi G, Ruggenenti P, Perico N: Chronic renal disease: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002, 136:604-615.
13. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
14. Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing micro-albuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
15. Wilmer WA, Hebert LA, Lewis EJ, et al.: Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the captopril study. Am J Kidney Dis 1999, 3:308.
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993, 329:1456-1462.
17. Bjorck S, Mulec H, Johnsen SA, et al.: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304:339.
18. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997, 349:1857.
19. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754-762.
20. de Zeeuw D, Ramjit D, Zhang Z, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309-2320.
21. Tarver-Carr M, Brancati F, Eberhardt M, et al.: Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J Am Soc Nephrol 2000, 11:168A.
22. Hoy WE, Wang Z, VanBuynder P, et al.: The natural history of renal disease in Australian Aborigines. Part I. Changes in albuminuria and glomerular filtration rate over time. Kidney Int 2001, 60:243-248.
23. Iseki K, Kinjo K, Iseki C, et al.: Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004, 44:806-814.
24. Aros C, Remuzzi G: The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens 2002, 20:S45-S53.
25. Shake JG, Brandt RC, Daniels BS: Angiotensin II induces actin polymerization within the glomerular filtration barrier: Possible role in the local regulation of ultrafiltration. J Am Soc Nephrol 1992, 3:568A.
26. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993-2000.
27. Rasoul S, Carretero OA, Peng H, et al.: Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004, 22:593-603.
28. Laverman GD, Remuzzi G, Ruggenenti P: ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol 2004, 15:S64-S70.
29. Komine N, Khang S, Wead LM, et al.: Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002, 39:159-164.
30. Azizi M, Chatellier G, Guyene TT, et al.: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995, 92:825-834.
31. Mulec H, Johnson SA, Wiklund O, et al.: Cholesterol: a renal risk factor in diabetic nephropathy. Am J Kidney Dis 1993, 26:196-201.
32. Keane WF: Lipids and the kidney. Kidney Int 1994, 46:910-920.
33. Samuelsson O, Mulec H, Knight-Gibson C, et al.: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997, 12:1908-1915.
34. Brouhard BH, Takamori H, Satoh S, et al.: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 1994, 8:436-440.
35. Oda H, Keane WF: Recent advances in statins and the kidney. Kidney Int 1999, 56:S2-S5.
36. Lee SK, Jin SY, Han DC: Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993, 8:1338-1343.
37. Zoja C, Coma D, Camozzi D, et al.: How to fully protect the kidney in a severe model of progressive nephropathy: a multi-drug approach. J Am Soc Nephrol 2002, 13:2898-2908.
38. Ruggenenti P Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001, 375:1601-1608.
39. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
40. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of are inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001, 37:477-483.
41. Lijnen P, Staessen J, Fagard R, Amery A: Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982, 49:1561-1563.
42. Naruse M, Tanabe A, Sato A, et al.: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002, 40:28-33.
43. Duprez D, De Buyzere M, Rietzschel ER, Clement DL: Aldosterone and vascular damage. Curr Hypertens Rep 2000, 2:327-334.
44. Schjoedt KJ, Rossing K, Juhl TR, et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006, 70:536-542.
45. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006, 1:256-262.
46. Delyani JA, Rocha R, Cook CS, et al.: Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001, 19:185-200.
47. Weber MA: Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. Rev Cardiovasc Med 2007, 8:S1-S6.
48. Takahashi H, Ichihara A, Kaneshiro Y, et al.: Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J Am Soc Nephrol 2007, 18:2054-2061.
49. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
50. Mann JF, Gerstein HC, Yi QL, et al.: Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003, 14:641-647.
51. Asselbergs FW, Diercks GF, Hillege HL, et al.: Effect of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110:2809-2816.